Here we reported the effect of carborane-containing therapeutics—ABCG2 inhibitors that were effective in low dosage, non-toxic to cancer cells, and performed in synergy when combined with doxorubicin and cisplatin. This evidence concerns the gene ABCG2 and cancer.